COMMUNIQUÉS West-GlobeNewswire

Summit Therapeutics plc : Block listing application

23/10/2017 - 13:45

Summit Therapeutics plc ("Summit" or the "Company") BLOCK LISTING APPLICATION Oxford, UK, 23 October 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing [...]

Genedrive PLC: genedrive launches Genedrive® Hepatitis C test in Africa

23/10/2017 - 13:00

genedrive plc ("genedrive" or the "Company") genedrive launches Genedrive® Hepatitis C test in Africa Genedrive® HCV ID Kit to be launched at IFCC WorldLab 2017 Congress genedrive plc (AIM: GDR), the near patient [...]

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines

23/10/2017 - 13:00

LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from [...]

Shire to Present New Data to Help Advance Understanding of Rare Diseases

23/10/2017 - 13:00

Shire to Present New Data to Help Advance Understanding of Rare Diseases Research to be presented at ACAAI 2017 Annual Scientific Meeting, reinforcing Shire's commitment to help patients living with hereditary [...]

Novo Nordisk A/S - Share repurchase programme

23/10/2017 - 12:55

Bagsværd, Denmark, 23 October 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Vistin Pharma ASA : Invitation to presentation of Q3 2017 results

23/10/2017 - 09:28

Oslo, 23 October 2017 Vistin Pharma ASA (OSE: VISTIN), a producer of high quality API's for the international pharmaceutical industry, will release its third quarter 2017 results on Friday 27 October 2017. The results [...]

NANOBIOTIX annonce avoir terminé l'inclusion des patients dans l'essai de phase II/III de NBTXR3 dans les Sarcome des Tissus Mous

23/10/2017 - 08:00

Nanobiotix annonce avoir terminé l'inclusion des patients dans l'essai de phase II/III de NBTXR3 dans les Sarcome des Tissus Mous Paris, France, et Cambridge, Massachusetts, USA, 23 octobre 2017 - NANOBIOTIX (Euronext: [...]

NANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma

23/10/2017 - 08:00

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma Paris, France and Cambridge, Massachusetts, USA, October 23, 2017 - NANOBIOTIX NANOBIOTIX (Euronext: NANO - ISIN: [...]

Ergomed's first-in-class haemostat, PeproStat(TM), reports positive top-line results and meets key endpoints in Phase II study

23/10/2017 - 08:00

PRESS RELEASE Ergomed's first-in-class haemostat, PeproStat(TM), reports positive top-line results and meets key endpoints in Phase II study Highly innovative blood free haemostat met the primary efficacy endpoint of [...]

Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients

23/10/2017 - 07:15

Breakthrough Therapy Designation based on Phase III study showing the three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] First targeted [...]

Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea

23/10/2017 - 07:15

Basel, Switzerland, October 23, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba ® (isavuconazole) in the United States exceeded the threshold triggering the first [...]

ABLYNX ANNOUNCES WARRANT EXERCISE

23/10/2017 - 07:00

REGULATED INFORMATION GHENT, Belgium, 23 October 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that [...]

First International Consensus Statement on the Clinical and Therapeutic Management of LHON published in the Journal of Neuro-Ophthalmology

23/10/2017 - 07:00

Liestal, Switzerland, October 23, 2017 - Santhera Pharmaceuticals (SIX:SANN) announces that the first International Consensus Statement on the Clinical and Therapeutic Management of Leber's Hereditary Optic Neuropathy ( [...]

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

23/10/2017 - 07:00

PRESS RELEASE TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601 Leuven (BELGIUM) - October 23, 2017, 7:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company [...]

La FDA américaine accorde à TiGenix l'appellation de médicament orphelin pour le Cx601

23/10/2017 - 07:00

COMMUNIQUÉ DE PRESSE La FDA américaine accorde à TiGenix l'appellation de médicament orphelin pour le Cx601 Louvain (BELGIQUE) - 23 octobre 2017, 07h. CEST - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société [...]

DBV Technologies annonce les résultats de l'étude clinique de phase III chez les enfants de 4 à 11 ans allergiques à l'arachide

20/10/2017 - 23:15

Communiqué de Presse Montrouge, France, le 20 Octobre; 10:35 pm CET DBV Technologies annonce les résultats de l'étude clinique de phase III chez les enfants de 4 à 11 ans allergiques à l'arachide DBV Technologies ( [...]

DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age

20/10/2017 - 23:15

Press Release Montrouge, France, October 20, 2017 DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age DBV Technologies (Euronext: DBV - ISIN: [...]

Silmäasema Oyj: Silmäasema supports the proposal of using client vouchers to pay for treating cataract and other eye diseases

20/10/2017 - 08:15

Silmäasema Corporation Press release 20 October 2017 at 9.15 EET Silmäasema supports the proposal of using client vouchers to pay for treating cataract and other eye diseases The draft government proposal regarding [...]

ThromboGenics Business Update - Q3 2017

20/10/2017 - 07:30

Press release 20 October, 2017 Regulated Information Diabetic Eye Disease programs progressing €53.7 million cash received from Alcon/Novartis in conjunction with regaining the non-US rights to JETREA Company's end Q3 [...]